---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-203000"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T09:17:14.743135+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Terns CEO Senthil Sundaram resigns for health reasons; Erin Quirk assumes leadership as principal executive officer

## Summary
- Senthil Sundaram resigned as CEO and Board member due to health reasons previously disclosed in January 2022.
- Erin Quirk, M.D., President and Head of R&D, assumed leadership effective immediately as principal executive officer.
- Sundaram will remain as a Senior Advisor to the company.
- Company plans three key clinical data readouts across three programs by end of 2024; balance sheet supports milestones.

## SEC filing metadata
- accession: 0001193125-23-203000
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000119312523203000/0001193125-23-203000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000119312523203000/d509174d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-203000
- JSON: https://secwatch.observer/filing/0001193125-23-203000.json
- Plain text: https://secwatch.observer/filing/0001193125-23-203000.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.